Journal of Drug Discovery and Therapeutics http://jddt.in/index.php/jddt <p><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;"><span style="text-align: justify;"><strong>Journal of Drug Discovery and Therapeutics (JDDT)</strong> is an international, peer-reviewed, open access, online journal dedicated to the rapid publication of full-length original research papers, short communications, invited reviews, Case studies and editorial commentary and news, Opinions &amp; Perspectives and Book Reviews written at the invitation of the Editor in all areas of the Biomedical and Pharmaceutical Sciences.</span></span></span></p> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;"><strong>Medical || Dentistry || Biomedical Sciences || Ayurveda || Homeopathy || </strong></span></span></p> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;">Anatomy, Physiology, Biochemistry, Molecular Biology, Cell biology, Genetics, Hematology, Pathology, Immunology, Microbiology, Virology, Parasitology, Surgery, Dental Sciences, Sports Physiology, Histopathology, Toxicology and all major disciplines of Biomedical Sciences.<br /><strong>Pharmaceutical Sciences || Allied Sciences </strong></span></span></p> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;">Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy and Phytochemistry, Pharmacology and Toxicology, Pharmaceutical and Biomedical Analysis, Clinical Research, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology and all major disciplines of Pharmaceutical Sciences.</span></span></p> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;">Articles are published as they are accepted and are freely available on the journal’s website to facilitate rapid and broad dissemination of research findings to a global audience.</span></span></p> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;"><strong>Top Reasons for publication with us</strong></span></span></p> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;"><strong>Quick Quality Review:</strong> The journal has strong international team of editors and reviewers, Rapid Decision and Publication</span></span></p> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;"><strong>Very Low Publication Fees:</strong> Comparable journals charge a huge sum for each accepted manuscript. JDDT only charge the fees necessary to recoup cost associated with running the journal</span></span></p> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;"><strong>Other features:</strong> DIDS Assigned and Implemented the Open Review System (ORS).</span></span></p> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;"><strong>Important Notice:</strong></span></span></p> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;">Author can now directly send their manuscript as an email attachment to</span></span></p> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;">Innovative Library</span></span></p> <p style="text-align: justify;"><span style="font-family: lucida sans unicode,lucida grande,sans-serif;"><span style="font-size: 14px;"><strong>editor@jddt.in</strong>, <strong>editorjddt.in@gmail.com</strong></span></span></p> <p> </p> JDDT en-US Journal of Drug Discovery and Therapeutics 2320-4230 AN OVERVIEW OF MANAGEMENT OF HYPERTENSION WITH ANGIOTENSIN-CONVERTING ENZYME INHIBITORS http://jddt.in/index.php/jddt/article/view/305 <p>ABSTRACT <br>Blockage of the renin-angiotensin system (RAS) is now recognized as an effective approach to the treatment of hypertension and congestive heart failure. Today, it is possible to antagonize the effects of angiotensin II (AT-II) more specifically by blocking its receptors by using non peptide receptor antagonists. AT-II-receptor antagonists were developed as agents that would more completely block the RAS and thus decrease the adverse effects seen with Angiotensin Converting Enzyme (ACE inhibitors). AT-II-receptor antagonists include losartan, valsartan, irbesartan, candesartan, eprosartan and telmisartan. The adverse effects of AT-II-receptor antagonists dizziness, headache, upper-respiratory- tract infection, cough, and gastrointestinal disturbances occur at about the same rate as with placebo. Four of them have recently been launched on the market and several others are preregistered for the treatment of hypertension. These new molecules are as effective as ACE inhibitors, calcium antagonists and beta-blockers in lowering blood pressure in hypertensive patients. When compared to ACE inhibitors, they appear to have comparable favorable effects on systemic and renal hemodynamic properties. All available AT-II-receptor antagonists seem to be equally effective in reducing both systolic and diastolic blood pressure. Currently, AT-II-receptor antagonists are used either as mono therapy in patients who cannot tolerate ACE inhibitors or in combination with other antihypertensive agents. In this review we summarize the combined therapy of ACE inhibitors and AT-IIreceptor antagonists play in ischemic heart disease. <br>KEYWORDS: Renin-angiotensin system, Hypertension, Angiotensin II receptor, Angiotensin Converting Enzyme inhibitors</p> Rupajit Bhattacharya Copyright (c) 2020 2017-12-30 2017-12-30 5 12